Transforming growth factor-β (TGF-β) induces the expression of chondrogenesis-related genes through TGF-β receptor II (TGFRII)-AKT-mTOR signaling in primary cultured mouse precartilaginous stem cells

Biochemical and Biophysical Research Communications

Volumn 450, Issue 1, 2014, Pages 646-651

  Li, Cheng ^a   Wang, Qiong ^a   Wang, Jun Fang ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

AKT; Chondrogenesis; mTOR; Precartilaginous stem cells; TGF

Indexed keywords

AGGRECAN; COLLAGEN TYPE 2; EVEROLIMUS; FIBROBLAST GROWTH FACTOR RECEPTOR 3; LINSIDOMINE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MESSENGER RNA; PROTEIN KINASE B; RECEPTOR ANTIBODY; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR SOX9; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; MTOR PROTEIN, MOUSE; ONCOPROTEIN; PROTEIN SERINE THREONINE KINASE; TARGET OF RAPAMYCIN KINASE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA TYPE II RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR;

ADULT STEM CELL; ANIMAL CELL; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL ISOLATION; CHONDROGENESIS; ENZYME ACTIVATION; GENE EXPRESSION; MESENCHYME CELL; MOUSE; NEWBORN; NONHUMAN; PHENOTYPE; PRECARTILAGINOUS STEM CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; AKT; ANIMAL; ARTICULAR CARTILAGE; C57BL MOUSE; CARTILAGE CELL; CYTOLOGY; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MTOR; PHYSIOLOGY; PRECARTILAGINOUS STEM CELLS; TGF-Β;

MUS;

AKT; CHONDROGENESIS; MTOR; PRECARTILAGINOUS STEM CELLS; TGF-Β;

ADULT STEM CELLS; ANIMALS; ANIMALS, NEWBORN; CARTILAGE, ARTICULAR; CELL DIFFERENTIATION; CELLS, CULTURED; CHONDROCYTES; CHONDROGENESIS; MICE; MICE, INBRED C57BL; ONCOGENE PROTEIN V-AKT; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TOR SERINE-THREONINE KINASES; TRANSFORMING GROWTH FACTOR BETA;

EID: 84904757331     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.06.030     Document Type: Article

References (34)

1. G. Tscheudschilsuren, A.K. Bosserhoff, J. Schlegel, D. Vollmer, A. Anton, V. Alt, R. Schnettler, J. Brandt, and G. Proetzel Regulation of mesenchymal stem cell and chondrocyte differentiation by MIA Exp. Cell Res. 312 2006 63 72
2. S. Zhang, A. Chen, W. Hu, M. Li, H. Liao, W. Zhu, D. Song, and F. Guo Immunological purification of rat precartilaginous stem cells and construction of the immortalized cell strain Arch. Orthop. Trauma Surg. 128 2008 1339 1344
3. D. Robinson, A. Hasharoni, N. Cohen, A. Yayon, R.M. Moskowitz, and Z. Nevo Fibroblast growth factor receptor-3 as a marker for precartilaginous stem cells Clin. Orthop. Relat. Res. 1999 S163 175
4. X. Guo, X. Chu, W. Li, Q. Pan, and H. You Chondrogenic effect of precartilaginous stem cells following NLS-TAT cell penetrating peptide-assisted transfection of eukaryotic hTGFbeta3 J. Cell. Biochem. 114 2013 2588 2594
5. E. Grimaud, D. Heymann, and F. Redini Recent advances in TGF-beta effects on chondrocyte metabolism. Potential therapeutic roles of TGF-beta in cartilage disorders Cytokine Growth Factor Rev. 13 2002 241 257
6. W. Ando, K. Tateishi, D.A. Hart, D. Katakai, Y. Tanaka, K. Nakata, J. Hashimoto, H. Fujie, K. Shino, H. Yoshikawa, and N. Nakamura Cartilage repair using an in vitro generated scaffold-free tissue-engineered construct derived from porcine synovial mesenchymal stem cells Biomaterials 28 2007 5462 5470
7. F. Djouad, D. Mrugala, D. Noel, and C. Jorgensen Engineered mesenchymal stem cells for cartilage repair Regen. Med. 1 2006 529 537
8. Y. Shi, and J. Massague Mechanisms of TGF-beta signaling from cell membrane to the nucleus Cell 113 2003 685 700
9. E. Piek, C.H. Heldin, and P. Ten Dijke Specificity, diversity, and regulation in TGF-beta superfamily signaling FASEB J. 13 1999 2105 2124
10. Y.E. Zhang Non-Smad pathways in TGF-beta signaling Cell Res. 19 2009 128 139
11. M.K. Lee, C. Pardoux, M.C. Hall, P.S. Lee, D. Warburton, J. Qing, S.M. Smith, and R. Derynck TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA EMBO J. 26 2007 3957 3967
12. T. Hayashida, M. Decaestecker, and H.W. Schnaper Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-beta-dependent responses in human mesangial cells FASEB J. 17 2003 1576 1578
13. A.R. Conery, Y. Cao, E.A. Thompson, C.M. Townsend Jr., T.C. Ko, and K. Luo Akt interacts directly with Smad3 to regulate the sensitivity to TGF-beta induced apoptosis Nat. Cell Biol. 6 2004 366 372
14. I. Remy, A. Montmarquette, and S.W. Michnick PKB/Akt modulates TGF-beta signalling through a direct interaction with Smad3 Nat. Cell Biol. 6 2004 358 365
15. M. Kato, S. Putta, M. Wang, H. Yuan, L. Lanting, I. Nair, A. Gunn, Y. Nakagawa, H. Shimano, I. Todorov, J.J. Rossi, and R. Natarajan TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN Nat. Cell Biol. 11 2009 881 889
16. S. Lamouille, and R. Derynck Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway J. Cell Biol. 178 2007 437 451
17. J.E. Chipuk, T. Kuwana, L. Bouchier-Hayes, N.M. Droin, D.D. Newmeyer, M. Schuler, and D.R. Green Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis Science 303 2004 1010 1014
18. E. Buck, A. Eyzaguirre, E. Brown, F. Petti, S. McCormack, J.D. Haley, K.K. Iwata, N.W. Gibson, and G. Griffin Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors Mol. Cancer Ther. 5 2006 2676 2684
19. P.B. Dennis, A. Jaeschke, M. Saitoh, B. Fowler, S.C. Kozma, and G. Thomas Mammalian TOR: a homeostatic ATP sensor Science 294 2001 1102 1105
20. L. Dudkin, M.B. Dilling, P.J. Cheshire, F.C. Harwood, M. Hollingshead, S.G. Arbuck, R. Travis, E.A. Sausville, and P.J. Houghton Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition Clin. Cancer Res. 7 2001 1758 1764
21. J.J. Gills, and P.A. Dennis Perifosine: update on a novel Akt inhibitor Curr. Oncol. Rep. 11 2009 102 110
22. H. Hirai, H. Sootome, Y. Nakatsuru, K. Miyama, S. Taguchi, K. Tsujioka, Y. Ueno, H. Hatch, P.K. Majumder, B.S. Pan, and H. Kotani MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo Mol. Cancer Ther. 9 2010 1956 1967
23. C.G. Proud MTORC1 signalling and mRNA translation Biochem. Soc. Trans. 37 2009 227 231
24. A. Duvoix, R. Blasius, S. Delhalle, M. Schnekenburger, F. Morceau, E. Henry, M. Dicato, and M. Diederich Chemopreventive and therapeutic effects of curcumin Cancer Lett. 223 2005 181 190
25. J. Ravindran, S. Prasad, and B.B. Aggarwal Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J. 11 2009 495 510
26. D.A. Guertin, and D.M. Sabatini Defining the role of mTOR in cancer Cancer Cell 12 2007 9 22
27. D.D. Sarbassov, D.A. Guertin, S.M. Ali, and D.M. Sabatini Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science 307 2005 1098 1101
28. G.D. Van Duyne, R.F. Standaert, P.A. Karplus, S.L. Schreiber, and J. Clardy Atomic structures of the human immunophilin FKBP-12 complexes with FK506 and rapamycin J. Mol. Biol. 229 1993 105 124
29. K.E. O'Reilly, F. Rojo, Q.B. She, D. Solit, G.B. Mills, D. Smith, H. Lane, F. Hofmann, D.J. Hicklin, D.L. Ludwig, J. Baselga, and N. Rosen MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Cancer Res. 66 2006 1500 1508
30. A. Carracedo, L. Ma, J. Teruya-Feldstein, F. Rojo, L. Salmena, A. Alimonti, A. Egia, A.T. Sasaki, G. Thomas, S.C. Kozma, A. Papa, C. Nardella, L.C. Cantley, J. Baselga, and P.P. Pandolfi Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer J. Clin. Invest. 118 2008 3065 3074
31. W.H. Chappell, L.S. Steelman, J.M. Long, R.C. Kempf, S.L. Abrams, R.A. Franklin, J. Basecke, F. Stivala, M. Donia, P. Fagone, G. Malaponte, M.C. Mazzarino, F. Nicoletti, M. Libra, D. Maksimovic-Ivanic, S. Mijatovic, G. Montalto, M. Cervello, P. Laidler, M. Milella, A. Tafuri, A. Bonati, C. Evangelisti, L. Cocco, A.M. Martelli, and J.A. McCubrey Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health Oncotarget 2 2011 135 164
32. E. Vilar, J. Perez-Garcia, and J. Tabernero Pushing the envelope in the mTOR pathway: the second generation of inhibitors Mol. Cancer Ther. 10 2011 395 403
33. H.Z. Huo, Z.Y. Zhou, B. Wang, J. Qin, W.Y. Liu, and Y. Gu Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014 Biochem. Biophys. Res. Commun. 443 2014 406 412
34. C. Garcia-Echeverria Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment Bioorg. Med. Chem. Lett. 20 2010 4308 4312